206P Characterization of the immune microenvironment of recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) that progress on or after platinum and anti-PD(L)1 therapies: An EORTC IMMUcan sub-project. (December 2022)